Catechol O-methyltransferase inhibition and the treatment of Parkinson's disease.
Nutt
J G
JG
Department of Neurology, Oregon Health Sciences University, Portland 97201, USA.
D000818:Animals; D000978:Antiparkinson Agents / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D001812:Blood-Brain Barrier; D001921:Brain / Q000378:metabolism; D065098:Catechol O-Methyltransferase Inhibitors; D002396:Catechols / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D004791:Enzyme Inhibitors / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D006801:Humans; D007408:Intestinal Absorption; D007980:Levodopa / Q000493:pharmacokinetics; D009570:Nitriles; D010300:Parkinson Disease / Q000188:drug therapy*; D014018:Tissue Distribution
D000978:Antiparkinson Agents; D065098:Catechol O-Methyltransferase Inhibitors; D002396:Catechols; D004791:Enzyme Inhibitors; D009570:Nitriles; D007980:Levodopa; C071192:entacapone